My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Articles published by Aptar Pharma

Aptar Pharma Continues Global Expansion with Opening of New R&D Center in France

September 25, 2025

From Aptar Pharma

Via Business Wire

Aptar Pharma’s Unidose System Delivers Enbumyst™, First U.S. FDA-Approved Intranasal Diuretic

September 18, 2025

From Aptar Pharma

Via Business Wire

Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis

September 05, 2025

From Aptar Pharma

Via Business Wire

Aptar’s First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon’s Otrivin® Brand

July 29, 2025

From Aptar Pharma

Via Business Wire

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

July 15, 2025

From Aptar Pharma

Via Business Wire

RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years

February 27, 2025

From Aptar Pharma

Via Business Wire

Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform

November 07, 2024

From Aptar Pharma

Via Business Wire

Aptar Pharma Acquires Device Technology Assets of SipNose to Further Expand Intranasal Drug Delivery Portfolio

October 09, 2024

From Aptar Pharma

Via Business Wire

Aptar Pharma Celebrates North America Capacity Expansion

September 24, 2024

From Aptar Pharma

Via Business Wire

Aptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler Platform

September 09, 2024

From Aptar Pharma

Via Business Wire

Aptar Pharma Continues Global Expansion with North America Capacity Extension at Congers, New York Site

March 14, 2024

From Aptar Pharma

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.